Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2013 2
2015 3
2017 2
2018 3
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol A, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Oñate G, et al. Among authors: hoyos m. Blood Adv. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. Blood Adv. 2022. PMID: 34516636 Free PMC article.
Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
Acha P, Hoyos M, Pratcorona M, Fuster-Tormo F, Palomo L, Ortega E, Zamora L, Vives S, Granada I, Montoro J, Garcia A, Arnan M, Cervera M, Canet M, Gallardo D, Arenillas L, Esteve J, Baragay J, Salamero O, Motlló C, Ortín X, Sierra J, Solé F. Acha P, et al. Among authors: hoyos m. Leuk Res. 2021 Feb;101:106492. doi: 10.1016/j.leukres.2020.106492. Epub 2021 Jan 11. Leuk Res. 2021. PMID: 33494038 Clinical Trial. No abstract available.
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia.
Pallarès V, Hoyos M, Chillón MC, Barragán E, Prieto Conde MI, Llop M, Falgàs A, Céspedes MV, Montesinos P, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Mangues R, Casanova I. Pallarès V, et al. Among authors: hoyos m. Cancers (Basel). 2018 Nov 13;10(11):436. doi: 10.3390/cancers10110436. Cancers (Basel). 2018. PMID: 30428571 Free PMC article.
NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients.
Pallarès V, Hoyos M, Chillón MC, Barragán E, Conde MIP, Llop M, Céspedes MV, Nomdedeu JF, Brunet S, Sanz MÁ, González-Díaz M, Sierra J, Casanova I, Mangues R. Pallarès V, et al. Among authors: hoyos m. Oncotarget. 2017 Jun 16;8(44):76003-76014. doi: 10.18632/oncotarget.18537. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100287 Free PMC article.
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M. Guillem V, et al. Among authors: hoyos m. Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345176
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.
Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD. Barragán E, et al. Among authors: hoyos m. Haematologica. 2015 May;100(5):e183-5. doi: 10.3324/haematol.2014.118117. Epub 2015 Jan 30. Haematologica. 2015. PMID: 25637054 Free PMC article. No abstract available.
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.
Santaliestra M, Garrido A, Carricondo M, Bussaglia E, Pratcorona M, Blanco ML, Gich I, Hoyos M, Esquirol A, García-Cadenas I, Brunet S, Martino R, Sierra J, Nomdedéu JF. Santaliestra M, et al. Among authors: hoyos m. Eur J Haematol. 2019 Sep;103(3):208-214. doi: 10.1111/ejh.13275. Epub 2019 Jul 3. Eur J Haematol. 2019. PMID: 31211880
Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.
García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF. García-Dabrio MC, et al. Among authors: hoyos m. Am J Clin Pathol. 2015 Sep;144(3):484-92. doi: 10.1309/AJCPRL6XSVFMLH9V. Am J Clin Pathol. 2015. PMID: 26276779
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF, Esquirol A, Carricondo M, Pratcorona M, Hoyos M, Garrido A, Rubio M, Bussaglia E, García-Cadenas I, Estivill C, Brunet S, Martino R, Sierra J. Nomdedéu JF, et al. Among authors: hoyos m. Biol Blood Marrow Transplant. 2018 Jan;24(1):55-63. doi: 10.1016/j.bbmt.2017.09.001. Epub 2017 Sep 20. Biol Blood Marrow Transplant. 2018. PMID: 28939453 Free article.
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Pratcorona M, et al. Among authors: hoyos m. Blood. 2013 Apr 4;121(14):2734-8. doi: 10.1182/blood-2012-06-431122. Epub 2013 Feb 1. Blood. 2013. PMID: 23377436 Free article.
14 results